Bone-free BMP

Thrasos built BMP activators to treat kidney injury, avoid unwanted bone growth

Thrasos Innovation Inc. believes its selective bone morphogenetic protein receptor activators will work for kidney disease because they trigger the BMP pathway's anti-inflammatory, anti-apoptotic and antifibrotic properties, but not its osteogenic properties.

BMP has been in development for kidney disease at least since the mid-'90s. In 1996, Creative BioMolecules Inc., now Curis Inc., presented data showing that bone morphogenetic protein 7 (BMP7; OP-1) protected against kidney damage in animal models

Read the full 695 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE